These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33912188)

  • 1. Triple-Negative Breast Cancer Cells Recruit Neutrophils by Secreting TGF-β and CXCR2 Ligands.
    SenGupta S; Hein LE; Xu Y; Zhang J; Konwerski JR; Li Y; Johnson C; Cai D; Smith JL; Parent CA
    Front Immunol; 2021; 12():659996. PubMed ID: 33912188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms underlying neutrophils adhesion to triple-negative breast cancer cells via CD11b-ICAM1 in promoting breast cancer progression.
    Yang C; Li L; Ye Z; Zhang A; Bao Y; Wu X; Ren G; Jiang C; Wang O; Wang Z
    Cell Commun Signal; 2024 Jun; 22(1):340. PubMed ID: 38907234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy.
    Shao S; Delk NA; Jones CN
    Sci Rep; 2024 Jun; 14(1):14142. PubMed ID: 38898176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.
    Wu L; Awaji M; Saxena S; Varney ML; Sharma B; Singh RK
    Am J Pathol; 2020 Jan; 190(1):222-233. PubMed ID: 31654638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-8: An evolving chemokine.
    Matsushima K; Yang D; Oppenheim JJ
    Cytokine; 2022 May; 153():155828. PubMed ID: 35247648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.
    Jablonska J; Wu CF; Andzinski L; Leschner S; Weiss S
    Int J Cancer; 2014 Mar; 134(6):1346-58. PubMed ID: 24154944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
    Tazzyman S; Barry ST; Ashton S; Wood P; Blakey D; Lewis CE; Murdoch C
    Int J Cancer; 2011 Aug; 129(4):847-58. PubMed ID: 21328342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β1 activates neutrophil signaling and gene expression but not migration.
    Hein LE; SenGupta S; Gunasekaran G; Johnson CN; Parent CA
    PLoS One; 2023; 18(9):e0290886. PubMed ID: 37682817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer.
    Ji HZ; Liu B; Ren M; Li S; Zheng JF; Liu TY; Yu HH; Sun Y
    Expert Rev Clin Immunol; 2024 May; 20(5):559-569. PubMed ID: 38224014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.
    Bohrer LR; Schwertfeger KL
    Mol Cancer Res; 2012 Oct; 10(10):1294-305. PubMed ID: 22893608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells.
    Taylor MA; Davuluri G; Parvani JG; Schiemann BJ; Wendt MK; Plow EF; Schiemann WP; Sossey-Alaoui K
    Breast Cancer Res Treat; 2013 Nov; 142(2):341-53. PubMed ID: 24197660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
    Kershaw MH; Wang G; Westwood JA; Pachynski RK; Tiffany HL; Marincola FM; Wang E; Young HA; Murphy PM; Hwu P
    Hum Gene Ther; 2002 Nov; 13(16):1971-80. PubMed ID: 12427307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.
    Perez Kerkvliet C; Dwyer AR; Diep CH; Oakley RH; Liddle C; Cidlowski JA; Lange CA
    Breast Cancer Res; 2020 May; 22(1):39. PubMed ID: 32357907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
    Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
    Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.